News

Joint FIND and NDWG symposium
11 Oct 2017

11 October 2017, 13:00 - 17:00
Expo Guadalajara Convention Centre, Guadalajara, Mexico

This year, FIND and the New Diagnostics Working Group (NDWG) joined in convening partners and members at a symposium which was held on 11 October back-to-back with the 48th Union World Conference on Lung Health.

During the symposium, we provided an overview of the most recent advances in the global TB diagnostics pipeline and reviewed progress made in various areas to address diagnostic needs towards ending the TB epidemic. Sessions focused on the use of next-generation sequencing for surveillance, diagnosis and patient management, and on the development of new tests for latent TB infection to support TB elimination.

The event also involved a round table discussion around the challenges in molecular testing roll-out on a programmatic level. Panelists considered how the interpretation of genetic mutations can guide clinical decision for treatment and shared different perspectives about the prospects of scaling up molecular approaches in different settings.

Agenda

Presentations

New Diagnostics Working Group Annual Meeting
26 Oct 2016

Wednesday, 26 October 2016, 9:00 - 12:30
Arena and Convention Centre, Liverpool, UK

The NDWG convened its Annual Meeting on 26 October 2016 at the 47th Union World Conference on Lung Health in Liverpool, UK.

NDWG Task Force members and partners reviewed progress in various areas of diagnostics R&D to support the targets of the End TB strategy and the Global Plan to End TB. Presentations covered newer understanding of LTBI diagnosis, as well as advanced drafts of the TPP for a test of progression of incipient TB and the Framework for evaluation of novel LTBI tests; the perspectives of next generation sequencing for detection of drug resistance in high TB burden countries; and a recent overview of the biomarker pipeline for TB detection at the point-of-care level, including for paediatric TB.

The presentations and audio are now available on the NDWG website as follows:

  • Agenda
  • Session I - Supporting TB elimination: Advances towards delivering new diagnostics for latent tuberculosis infection
  • Session II - Next Generation Sequencing for improved management of patients with drug resistant TB
  • Session III - Advancing biomarker discovery for TB point-of-care tests
NDWG launches consultation on draft TPP for a test of progression of LTBI
1 Jun 2016

The New Diagnostics Working Group and its Task Force on tests for progression of LTBI to active disease have recently launched an online consultation to gather input on a draft Target Product Profile (TPP) for a test of progression of latent tuberculosis infection (LTBI).

Reactivation of LTBI is the source of the vast majority of new TB cases in low transmission areas. As global TB incidence declines, preventing progression from LTBI to active TB will be crucial for cutting transmission and reaching the goal of TB elimination. The introduction of targeted and cost-effective treatment of individuals with LTBI requires a diagnostic test to identify the small proportion of latently infected persons who will progress to active disease.

A prognostic test for determining the risk of progression from LTBI to active disease is currently unavailable. To support the development of this new test, FIND has defined a draft TPP with contribution from the NDWG LTBI Task Force and other experts in the field. This document will provide guidance to diagnostic developers as to the key characteristics that the test needs to fulfill in order to meet requirements.

The NDWG is conducting an online survey to gather input from a group of stakeholders representing researchers, endemic countries, governmental and non-governmental organizations, test developers and the patient community. Participants will have the opportunity to evaluate the key performance and operational characteristics as defined in the TPP in order to build large consensus. Results will be discussed by an expert group which will be convened by the NDWG Task Force on LTBI on July 1st 2016 in Milan, Italy, in order to finalize the TPP and submit the document to WHO for endorsement.

More information about the NDWG Task Force on LTBI

NDWG Annual Meeting 2015
3 Dec 2015

CTICC - International convention centre, Cape Town, South Africa

The Annual Meeting of the New Diagnostics Working Group was held on 3 December 2015 at the 46th Union World Conference in Cape Town. The meeting reviewed three main areas of activity in which the NDWG has engaged to advance TB diagnostics research and development. In the first session we examined the promises of next generation sequencing for detection of anti-microbial resistance and presented progress on the development of the ReSeqTB data sharing platform. Presentations in the second session discussed the new priorities for drug susceptibility testing in order to ensure the successful adoption of new TB drug regimens and highlighted the role of laboratory-based approaches. The third session focused on the development of tests for progression of latent TB to active disease, which are required to efficiently introduce targeted preventive therapy and support the goal of TB elimination. In particular, we reported on the outcomes of an expert meeting organized by the NDWG in collaboration with partners and shared the latest updates on the development of target product profiles and study protocols.

Agenda

Presentations and session audio

10 million lives saved and 45 million TB cases avoided with Stop TB Partnership 5-year investment plan
20 Nov 2015

The Stop TB Partnership launches the new Global Plan to End TB 2016-2020 - The Paradigm Shift

The world is losing its battle with tuberculosis (TB), which is now the biggest infectious killer globally, causing 1.5 million deaths every year. Without a clear investment plan and a complete overhaul in how this disease is tackled, TB is unlikely to be eliminated until the end of the 22nd century, and the world will miss the recently announced Sustainable Development Goal to end TB by 2030.

This will require a US$ 56 billion investment package from 2016-20, which will see 29 million people with TB receive treatment; save more than 10 million lives and prevent 45 million people from getting ill with TB. This investment will offer a huge return for affected individuals, their families, and their communities, and one of the highest returns on investment of any health intervention - an estimated US$ 85 for each dollar invested. This is clearly outlined in the new Global Plan to End TB 2016 -2020 launched by Stop TB Partnership.

The battle with TB cannot be won without new tools. For this, as part of the total package, the Global Plan calls for a US $9 billion investment needed for vital research and development to create a vaccine that protects people of all ages against TB, highly sensitively rapid diagnostic tests that can be implemented at the point of care, and drug regimens (including for drug-resistant TB) that are highly effective and non-toxic. Read more...

Access to key documents

International partnership to create global TB data sharing platform
26 Jan 2015

The NDWG is partnering with CPTR, FIND and a consortium of other international stakeholders to develop a Rapid DST Data Sharing Platform. The initiative addresses the need for a centralized data resource for globally diverse genomic and other clinically relevant tuberculosis data. Data contributed from a variety of research, academic and government bodies will be reviewed for quality in a transparent manner, standardized, and eventually made accessible to TB researchers and clinicians. This collaborative effort will contribute to advance the understanding of genetic mutations and mechanisms associated with drug resistance, thus supporting the development of new diagnostic tests to detect drug-resistant TB. News release

NDWG activities in support of data sharing
3 Feb 2014

Presentations and meeting reports are available here.

Facilitating coordination of TB diagnostic research: NDWG workshop on sequencing data sharing

On 3-4 February 2014, the New Diagnostics Working Group held a workshop on "Enabling standards and sharing of data on the molecular basis of drug resistance" in London, UK. The event was jointly organized with the Critical Path to TB Drug Regimens (CPTR).The meeting aimed at establishing standards for the exchange of next generation sequencing data and for the combination with phenotypic DST results and clinical outcome. Participants also discussed possible mechanisms for sharing and making accessible this data to test developers, researchers, clinicians, and institutions performing diagnostics for treatment. This meeting is a successful example of how the NDWG provides a neutral coordination platform for multiple stakeholders in TB diagnostic R&D, thus playing a central convening role.

NDWG Co-Chairs, Dr Daniela Cirillo, San Raffaele Research Institute, and Dr Mark Perkins, FIND, chaired the meeting, which attracted 55 invited participants. These included experts from different backgrounds, such as TB sequencing groups, TB reference laboratories, TB clinicians, software developers, test developers, diagnostics industry, patent attorney, funding bodies, WHO, US CDC, ECDC, the European Commission, PHE and NGOs. The two-day workshop comprised of information sharing through presentations from attendees and circulation of published documents. The format of the event enabled focused debate in breakout groups and several plenary discussions aimed at consensus building.

The agenda and presentations are available under Meetings.

NDWG Annual Meeting 2012
13 Nov 2013

The New Diagnostics Working Group held its Annual Meeting 2012 in conjunction with the 43rd Union World Conference on Tuesday, 13 November 2012, in Kuala Lumpur, Malaysia

Agenda
Presentations

NDWG Annual Meeting 2013
31 Oct 2013

Moving to point-of-care diagnosis (symposium and panel discussion)

31 October 2013, 9:00 - 12:30, Room Havane, Palais des Congrès, Paris, France

The New Diagnostics Working Group held its Annual Meeting 2013 in conjunction with the 44th Union World Conference on Thursday, 31 October 2013 in Paris, France.

In the meeting we reviewed scientific and technological advances that could foster the development of rapid point-of-care tests for TB.

Speakers highlighted the importance of global coordination for successful development of new TB diagnostics and discussed challenges for adoption and scale-up. Presenters also gave updates on progress made in biomarker discovery and whole genome sequencing, and introduced novel promising technologies. A panel discussion on priorities and approaches to address existing barriers to delivering point-of-care tests for TB closed the session.

Agenda | Presentations | Videos

NDWG to host a symposium at ESM Congress 2013
30 Jun 2013

The Annual Congress of the European Society of Mycobacteriology will be held in Florence, Italy, from 30 June - 3 July 2013.

The NDWG will be hosting a symposium on Monday 1st July 2013 from 16:15 - 17:15. The session will focus on the role of next-generation sequencing for patient care and will include the following presentations:

  • Rapid whole genome sequencing as a tool to manage MDR/XDR-TB patients, Prof. Philip D Butcher, St George's University of London
  • Lessons on drug resistance from WGS of one thousand clinical isolates, Dr. Taane Clark, London School of Hygiene and Tropical Medicine
  • Low density microarrays as potential tools for DST in M. tuberculosis, Dr. Paolo Miotto, San Raffaele Scientific Institute

For more information on the congress, please visit www.esmcongress.org